In an apparent first for a generic drug company with an excellent manufacturing record, FDA has served Mylan NV with a warning letter
for cGMP failures at its Caguas, Puerto Rico finished pharmaceuticals manufacturing plant.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?